Incyte Corporation vs LYFT Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while LYFT Inc trades at $17.52 (market cap $6.64B). The key difference: Incyte Corporation is far larger — about 3.7× LYFT Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| INCY | LYFT | |
|---|---|---|
Market Cap | $24.54B | $6.64B |
Sector | Health | Industrials |
52-Week High | $129.93 | $24.57 |
52-Week Low | $81.61 | $12.65 |
Enterprise Value | $20.04B | $6.11B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →